RegeneRx receives Australian patent for use of Thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex: RGN) (the "Company" or "RegeneRx") today announced it has received Notice of Acceptance from the Australian patent office for the use of Thymosin beta 4 (Tβ4), its analogues, isoforms and other derivatives in the treatment of infections and inflammatory disorders including colitis, ileitis, gastrointestinal ulcers and gingivitis, among others. The patent expires in 2023. This is one of several patents the Company has been granted in Australia related to its technology and drug candidates.

"We are pleased to enhance our global intellectual property estate for our product candidates and their potential uses," said J.J. Finkelstein, president and CEO of RegeneRx Biopharmaceuticals. "We currently have more than 60 issued patents and patent applications throughout the world that expire between 2019 and 2027."